Publication
UK Carbon Border Adjustment Mechanism: how will it work?
In February, we reported on the Department of Energy Security and Net Zero’s confirmation that a UK Carbon Border Adjustment Mechanism (CBAM) would be bought into force by 2027
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Publication
In February, we reported on the Department of Energy Security and Net Zero’s confirmation that a UK Carbon Border Adjustment Mechanism (CBAM) would be bought into force by 2027
Publication
International financial markets have started to show significant interest in nature and biodiversity. Whilst climate change and greenhouse gas emissions have made the headlines in recent years, there has been much less focus on their equally important counterparts, nature and biodiversity. However, that has started to change.
Publication
In April 2024, the UK Government published details of its sustainable aviation fuel mandate (the UK SAF Mandate) and launched a consultation on proposals for a revenue certainty mechanism to support UK sustainable aviation fuel (SAF) production.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023